Dhanuka Agritech Q1 FY2027: Monsoon delays hit sales, while the company lines up new launches and a Nagpur expansion

Dhanuka Agritech reported a weaker start to FY2027 as delayed monsoon onset in several key regions pushed sowing activity into later months. For Q1 FY2027, revenue from operations came in at INR 461.93 crore versus INR 528.29 crore in Q1 FY2026, a decline of 12.56%. Profitability compressed as well: EBITDA fell to INR 55.01 crore from INR 83.19 crore, while PAT declined to INR 36.30 crore from INR 55.50 crore.

Management framed the quarter as a cyclical setback driven by weather disruptions, softer domestic demand, and competitive pricing. The Chairman highlighted that rainfall shortfall in June materially affected sowing and early-season product demand, with some normalization by end-July. The call also acknowledged elevated raw material and logistics costs and indicated that attempted price increases early in the season did not sustain.

What changed in the mix: herbicides remained largest, but took the hit

Dhanuka’s revenue remains well spread across product categories, but Q1 FY2027 reflected the stress in herbicide-heavy geographies. Segment mix for the quarter was led by herbicides at 42% of revenue, followed by insecticides at 25%, fungicides at 14% and others at 19%.

Management explained that Q1 is typically herbicide heavy for the company, particularly linked to soybean and cotton belts. States such as Rajasthan, Gujarat, Madhya Pradesh and Maharashtra saw weaker rainfall in June, including pockets requiring re-sowing. This impacted herbicide demand and was visible in the quarter’s performance.

Fungicides were the relative bright spot. Rahul Dhanuka noted that while fungicides are usually stronger in Q2, certain horticulture-linked fungicides saw traction even in Q1 due to dry-season use and strong horticulture prices. He specifically cited Nissodium and Conika as drivers.

Innovation and launches: ITI moderated, but pipeline stays active

Dhanuka continues to measure new product performance using its Innovation Turnover Index, which tracks revenue contribution from new molecules. In the presentation, ITI has risen steadily over multiple years, reaching 14.93% in FY2026. In Q1 FY2027, ITI was disclosed at 11.56%, down from 13.39% in Q1 FY2026.

On the call, management reiterated that product economics vary by category. Patented and differentiated products, including 9(3) products and nutrition solutions, typically command premium margins compared to me-too and co-marketing products. Rahul Dhanuka stated that the company benchmarks a minimum 20% margin for any new product introduction, while differentiated categories can be materially higher.

Near-term product activity remains active. The Chairman and management reiterated plans to launch five new products in the coming months, comprising one liquid fertilizer, three fungicides and one herbicide. This is positioned as part of the company’s broader push to strengthen growth through new chemistries and product development.

A second theme is bio-stimulants. Management said the company is rebuilding this category, with two out of three products already introduced and the third expected to be launched by end-August 2026. Approvals and sale permissions have been received in most states. The company also indicated that the regulatory framework could reduce space for smaller, unorganized players, potentially improving share prospects for organized participants depending on on-ground enforcement.

Capacity and capital allocation: Nagpur plant planned, Dahej ramps slowly

One of the most material strategic updates was the new facility plan in Nagpur, Maharashtra. The Chairman disclosed that the company has acquired land at Nagpur to set up a new manufacturing plant, citing the expiry of incentives available to the Udhampur unit in March 2026. Total estimated outlay for the project is expected to be up to INR 200 crore with a planned capacity of 23,000 MT per annum. The plant is expected to be operational by April 2028, also described as Q4 FY2028.

In the Q&A, management clarified that the Nagpur project will be a formulation unit, not a technical synthesis plant like Dahej. Rahul Dhanuka also said the facility is envisioned as a significantly automated plant with a global standard on safety and efficiency, which partly explains the higher capital intensity versus a typical formulation unit. However, management did not quantify expected returns or asset turns and said they will address the details once the project is finalized.

Dahej, the company’s technical synthesis facility, remains a work in progress. The CFO disclosed that Dahej revenue in Q1 was INR 26 crore versus INR 16 crore in the same quarter last year. EBITDA for Dahej improved from a negative INR 3 crore last year to less than INR 1 crore loss this year for the quarter. For FY2027, management guided Dahej revenue at around INR 65 crore, but also indicated that breakeven at EBITDA level appears difficult and could remain in the range of negative INR 4 to 5 crore.

The company also reiterated shareholder returns actions. The Chairman highlighted a buyback of 5 lakh equity shares at INR 1,400 per share, amounting to INR 70 crore. The AGM considered a final dividend of 100%, equivalent to INR 2 per equity share of face value INR 2, with results to be declared in due course.

What management is guiding now

The investor presentation included FY2027 guidance updates. Management guided for lower single digit growth in revenue from operations and an expected EBITDA margin decline of approximately 200 bps.

On the Bayer fungicide brands acquired earlier, management commentary was cautious on near-term financial contribution. The CFO said Bayer product revenue was not meaningfully reflected in Q1 and indicated seasonality, with a product linked to grapes expected to contribute in Q2, including in September. Management did not provide a quantitative FY2027 revenue estimate for these brands and indicated export-side initiatives are underway, including incorporating entities in Brazil and Europe, but the contribution in the current year is expected to be not significant.

The key takeaway from Q1 is that the company has shifted to a more conservative stance for FY2027, reflecting the on-ground realities of a delayed monsoon and softer early demand. At the same time, Dhanuka is maintaining its longer-term playbook: deepen differentiated launches, rebuild bio-stimulants, and expand formulation capacity through the planned Nagpur facility with an April 2028 target. Execution and visibility on returns from new capacity, along with the pace of Dahej scaling, will remain central areas for investors to track over the next few quarters.